{
    "id": 9533,
    "fullName": "FGFR2 L618M",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR2 L618M (corresponds to L617M in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L618M results in increased Fgfr2 kinase activity, enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597), and elevated kinase activity compared to wild-type Fgfr2 protein in substrate phosphorylation assays (PMID: 28166054).",
            "references": [
                {
                    "id": 14787,
                    "pubMedId": 28166054,
                    "title": "Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28166054"
                },
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2263,
        "geneSymbol": "FGFR2",
        "terms": [
            "FGFR2",
            "BBDS",
            "BEK",
            "BFR-1",
            "CD332",
            "CEK3",
            "CFD1",
            "ECT1",
            "JWS",
            "K-SAM",
            "KGFR",
            "TK14",
            "TK25"
        ]
    },
    "variant": "L618M",
    "createDate": "07/23/2015",
    "updateDate": "05/23/2019",
    "referenceTranscriptCoordinates": {
        "id": 175995,
        "transcript": "NM_022970",
        "gDna": "chr10:g.121496546A>T",
        "cDna": "c.1852T>A",
        "protein": "p.L618M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2600,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",
            "molecularProfile": {
                "id": 9492,
                "profileName": "FGFR2 L618M"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",
            "molecularProfile": {
                "id": 9492,
                "profileName": "FGFR2 L618M"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597).",
            "molecularProfile": {
                "id": 9492,
                "profileName": "FGFR2 L618M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2138,
                    "pubMedId": 23908597,
                    "title": "The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23908597"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9492,
            "profileName": "FGFR2 L618M",
            "profileTreatmentApproaches": [
                {
                    "id": 7506,
                    "name": "FGFR2 Inhibitor",
                    "profileName": "FGFR2 L618M"
                },
                {
                    "id": 7507,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR2 L618M"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 175997,
            "transcript": "NM_001144913",
            "gDna": "chr10:g.121496546A>T",
            "cDna": "c.1852T>A",
            "protein": "p.L618M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 175995,
            "transcript": "NM_022970",
            "gDna": "chr10:g.121496546A>T",
            "cDna": "c.1852T>A",
            "protein": "p.L618M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 175996,
            "transcript": "XM_017015925",
            "gDna": "chr10:g.121485444G>T",
            "cDna": "c.1852C>A",
            "protein": "p.L618M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}